IL174763A0 - TREATMENT OF DISEASES INVOLVING ErbB2 KINASE OVEREXPRESSION - Google Patents
TREATMENT OF DISEASES INVOLVING ErbB2 KINASE OVEREXPRESSIONInfo
- Publication number
- IL174763A0 IL174763A0 IL174763A IL17476306A IL174763A0 IL 174763 A0 IL174763 A0 IL 174763A0 IL 174763 A IL174763 A IL 174763A IL 17476306 A IL17476306 A IL 17476306A IL 174763 A0 IL174763 A0 IL 174763A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- diseases involving
- erbb2 kinase
- kinase overexpression
- involving erbb2
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002018 overexpression Effects 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51060403P | 2003-10-10 | 2003-10-10 | |
| PCT/US2004/033355 WO2005034879A2 (en) | 2003-10-10 | 2004-10-08 | Treatment of diseases involving erbb2 kinase overexpression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL174763A0 true IL174763A0 (en) | 2008-04-13 |
Family
ID=34435110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL174763A IL174763A0 (en) | 2003-10-10 | 2006-04-03 | TREATMENT OF DISEASES INVOLVING ErbB2 KINASE OVEREXPRESSION |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050245601A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1670455A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007508316A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1889944A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004280257A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2541548A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL174763A0 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2006115615A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005034879A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2435578C2 (ru) * | 2005-06-29 | 2011-12-10 | Марс, Инкорпорейтед | Возбуждение вазодилатации периферических кровеносных сосудов |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| AU2006331531B2 (en) * | 2005-12-23 | 2013-01-31 | Mars, Incorporated | Skin protection and improvement |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2009536667A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | ５ｈｔ受容体介在性の神経新生 |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20100254996A1 (en) * | 2007-06-18 | 2010-10-07 | Medimmune, Llc | Synergistic treatment of cells that express epha2 and erbb2 |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5554645A (en) * | 1994-10-03 | 1996-09-10 | Mars, Incorporated | Antineoplastic cocoa extracts and methods for making and using the same |
| WO1997036497A2 (en) * | 1996-04-02 | 1997-10-09 | Mars, Incorporated | Cocoa extract compounds and methods for making and using the same |
| US6297273B1 (en) * | 1996-04-02 | 2001-10-02 | Mars, Inc. | Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions |
| US6207842B1 (en) * | 1997-10-09 | 2001-03-27 | Mars Incorporated | Process for preparing procyanidin(4-6 or 4-8) oligomers and their derivatives |
| US6156912A (en) * | 1999-04-09 | 2000-12-05 | Mars, Incorporated | 88, 66, and 68 catechin and epicatechin dimers and methods for their preparation |
| US7015338B1 (en) * | 1999-04-15 | 2006-03-21 | Mars Incorporated | Synthetic methods for preparing procyanidin oligomers |
-
2004
- 2004-10-08 RU RU2006115615/14A patent/RU2006115615A/ru not_active Application Discontinuation
- 2004-10-08 EP EP04809906A patent/EP1670455A4/en not_active Withdrawn
- 2004-10-08 US US10/961,992 patent/US20050245601A1/en not_active Abandoned
- 2004-10-08 CA CA002541548A patent/CA2541548A1/en not_active Abandoned
- 2004-10-08 CN CNA2004800362204A patent/CN1889944A/zh active Pending
- 2004-10-08 WO PCT/US2004/033355 patent/WO2005034879A2/en not_active Ceased
- 2004-10-08 AU AU2004280257A patent/AU2004280257A1/en not_active Abandoned
- 2004-10-08 JP JP2006534418A patent/JP2007508316A/ja not_active Abandoned
-
2006
- 2006-04-03 IL IL174763A patent/IL174763A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20050245601A1 (en) | 2005-11-03 |
| RU2006115615A (ru) | 2007-11-27 |
| CN1889944A (zh) | 2007-01-03 |
| AU2004280257A1 (en) | 2005-04-21 |
| JP2007508316A (ja) | 2007-04-05 |
| WO2005034879A3 (en) | 2005-12-29 |
| WO2005034879A2 (en) | 2005-04-21 |
| EP1670455A2 (en) | 2006-06-21 |
| EP1670455A4 (en) | 2008-10-15 |
| CA2541548A1 (en) | 2005-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL227841A0 (en) | Dihydropyridinones for the treatment of cancer | |
| EG24420A (en) | Treatment of ophthalmic conditions | |
| IL169602A0 (en) | Methods of treating lung diseases | |
| EP1617844A4 (en) | TREATMENT OF NEUROLOGICAL DISEASES | |
| GB0404656D0 (en) | Treatment of spinal conditions | |
| GB0329874D0 (en) | Compounds useful for the treatment of diseases | |
| EP1680145A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
| GB0320238D0 (en) | Treatment of disease | |
| IL174763A0 (en) | TREATMENT OF DISEASES INVOLVING ErbB2 KINASE OVEREXPRESSION | |
| EP1691776A4 (en) | TREATMENT OF AIDS | |
| GB2410744B (en) | Kinase inhibitors for the treatment of disease | |
| GB0329416D0 (en) | Treatment of cancer | |
| GB0317500D0 (en) | Treatment of bph | |
| GB0327975D0 (en) | Methods of treatment | |
| GB0410379D0 (en) | Treatment of cancer | |
| ZA200606780B (en) | Compounds for the treatment of diseases | |
| GB0423273D0 (en) | Treatment of cancer | |
| HU0302933D0 (en) | Treatment of diseases | |
| GB0325957D0 (en) | The treatment of pain | |
| PT1706094T (pt) | Tratamento de condições oftalmológicas | |
| GB0407710D0 (en) | Treatment of diseases | |
| GB0319715D0 (en) | Treatment of auto-inflammatory disease | |
| GB0327667D0 (en) | Treatment of cancer | |
| GB0208194D0 (en) | Treatment of disease | |
| GB0322921D0 (en) | Methods of treatment |